It is currently Sun Apr 30, 2017 7:30 pm

News News of Campath (Lemtrada, Alemtuzumab)

Site map of Campath (Lemtrada, Alemtuzumab) » Forum : Campath (Lemtrada, Alemtuzumab)

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

Mechanism found for Alemtuzumab side effect

Researchers think they may have figured out why a drug that is highly effective against one autoimmune disease can sometimes trigger another.... Read More -
Read more : Mechanism found for Alemtuzumab side effect | Views : 2556 | Replies : 1

Infusion duration

I have a simple question for anyone that has been on Lemtrada. How long does each individual
infusion take? Is it about an hour or all day?

I just stopped Tysabri after 73 infusions (JCV+). I am waiting for my Tecfidera script to get here.

I like to stay current with what new treatments are coming.
Nothing looks more promising than Lematrada to me. 5 infusions then a year later 3 more.
If I understand ...
Read more : Infusion duration | Views : 2504 | Replies : 1

Genzyme boasts of durable response to MS drug Lemtrada

Genzyme boasts of durable response to MS drug Lemtrada

Looking ahead to a prospective FDA approval of its experimental multiple sclerosis drug Lemtrada and a new product launch into a competitive and fast-changing market, Genzyme executives today rolled out positive data from a one-year extension study of its pivotal Phase III trial that gives the company some boasting rights for a drug that demonstrated a durable response in most patients..... Read More -
Read more : Genzyme boasts of durable response to MS drug Lemtrada | Views : 2627 | Replies : 2

Alemtuzumab lessens relapses, improves disability in MS

Alemtuzumab lessens relapses, improves disability in MS - studies


Two new trials offer proof that a leukemia drug long used to treat multiple sclerosis works better than a common treatment.

When compared with the widely used drug interferon beta, the leukemia drug alemtuzumab reduced relapse rates by half, researchers say.

Alemtuzumab Reverses Disability in Some

Alemtuzumab has been used to treat MS for close to two decades, but it has never been approved for ...
Read more : Alemtuzumab lessens relapses, improves disability in MS | Views : 3712 | Replies : 3

FDA refuse to file letter

The FDA have sent Genzyme/Sanofi a refuse to file letter. They're not asking for more trials, just for more info at the moment, but it will put back approval in the US by another 6 months or so. The EMA in Europe have accepted the application.
Read more : FDA refuse to file letter | Views : 2527 | Replies : 0

pseudo relapses after Campath

I had one high dose of Campath 2-3 years ago. I got ITP and could not have another dose. I have not had any major relapses since the treatment. However, I have had and am currently experiencing pseudo relapses where I have worsening symptoms and periods of increased disability, which come and go frequently. I am not sure if I should even report these to my neuro. It is hard to tell. HAs anyone experienced ...
Read more : pseudo relapses after Campath | Views : 4250 | Replies : 8

Withawal of campath

Apparently in the US and most of Europe, Sanofi are withdrawing the unlicensed use of Campath for MS treatment ie use outside of a recognised trial. Drs. will only be able to get it for named cancer patients. I think this starts in the US in November. This is in preparation for it to be licensed under Lemtrada once the EMA and FDA have looked at it.
Read more : Withawal of campath | Views : 2536 | Replies : 0

Shingles - lucky me -NOT

I had a third dose of alamtuzumab a couple months ago. I took the acyclovir as instructed and all was good but I took my triplets for a well visit and they got the chicken pox booster. I didn't think about it because I've had chicken pox. I forgot about the possibility of getting shingles and now I have them. Please keep it in mind when you get you doses.
Read more : Shingles - lucky me -NOT | Views : 2379 | Replies : 0

Approval sought for Lemtrada(TM) (alemtuzumab) for MS


Genzyme, a Sanofi company , today announced that the company has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of Lemtrada(TM) (alemtuzumab) for treatment of relapsing multiple sclerosis (RMS). Genzyme is developing Lemtrada in MS in collaboration with Bayer HealthCare.

Genzyme's clinical development program for Lemtrada included two Phase III studies in which ...
Read more : Approval sought for Lemtrada(TM) (alemtuzumab) for MS | Views : 2809 | Replies : 0

Lemtrada (alemtuzumab) improved disability scores in MS pts

Lemtrada (alemtuzumab) improved disability scores in MS patients over Rebif


Genzyme, a Sanofi company , reports today additional data from the Phase III CARE-MS II trial. Accumulation of disability was significantly slowed in patients with multiple sclerosis (MS) who were treated with alemtuzumab versus Rebif(R) (high dose subcutaneous interferon beta-1a), as measured by the Expanded Disability Status Scale (EDSS), a standard assessment of physical disability progression.

In addition, significant improvement in disability scores was ...
Read more : Lemtrada (alemtuzumab) improved disability scores in MS pts | Views : 3129 | Replies : 0


Login  •  Register


Total posts 237714 • Total topics 25832 • Total members 17106

Contact us | Terms of Service